TrialNet is testing rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extend insulin production in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D). Each therapy has a history of safety and effectiveness. Rituximab-pvvr is FDA-approved to...
For people age 12 – 35 years who have been diagnosed with type 1 diabetes in the past 3 months, this study tests two JAK inhibitors (abrocitinib and ritlecitinib) to see if either or both can preserve insulin production. TrialNet researchers are testing two different JAK...
[box class="summary"][/box]We are inviting you to participate in a research study to help us improve our understanding of diabetes and immune mediated diseases. The study consists of a computer registry where we store your contact, research, and health information, and a sample repository where we...
[box class="summary"][/box]TrialNet’s Pathway to Prevention studies the development of type 1 diabetes, and screens relatives of people with type 1 diabetes for their risk of developing the disease. Relatives of people with type 1 diabetes have about a 3 to 4 percent chance of being...
